Fig. 6

AT-hMSCs can suppress C3 expression in vivo A C3 expression in liver, colon and lung samples on day 21 post-transplantation. C3 staining in green, DAPI in blue. Scale bar = 50 μm. Atorvastatin or erlotinib can upregulate CD55 and protect complement lysis of hMSCs upon serum incubation. CD55 mRNA expression (B and C), and surface protein expression (D) in hMSCs upon treatment with atorvastatin or erlotinib for 24 h. Atr: Atorvastatin; Erl: erlotinib. E %C3b deposition on hMSCs upon treatment with atorvastatin or erlotinib for 24 h. Graphs show data (mean +/− SEM) of three to four experiments performed in triplicate. Significance was calculated relative to control cells *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001